Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Viread

Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14

HOS-110514 · Präparat HOS-093385

13  Medicinal product by Effects on drug levels Recommendation concerning therapeutic areas Mean percent change in AUC, co-administration with 245 mg (dose in mg) Cmax, Cmin tenofovir disoproxil Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma concentrations (400 mg/100 mg q.d.) + AUC: ↔ of tenofovir resulting from Atazanavir/Ritonavir Cmax: ↔ co-administration of tenofovir (300 mg q.d./100 mg q.d.) + disoproxil, sofosbuvir/velpatasvir Emtricitabine/Tenofovir disoproxil GS-3310072: and atazanavir/ritonavir may (200 mg/245 mg q.d.) AUC: ↔ increase adverse reactions related Cmax: ↔ to tenofovir disoproxil, including Cmin: ↑ 42% renal disorders. The safety of tenofovir disoproxil when used Velpatasvir: with sofosbuvir/velpatasvir and a AUC: ↑ 142% pharmacokinetic enhancer (e.g. Cmax: ↑ 55% ritonavir or cobicistat) has not Cmin: ↑ 301% been established.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) ritonavir (HOS-084521) emtricitabine (HOS-085840)